AKT1 and neoplasm: As shown in Figure 6B–D, while treatment with the AKT inhibitor (MK2206), which significantly inhibits AKT activation in the transplanted NCI‐H82‐shCKB tumors, did not significantly impact the growth of NCI‐H82‐shCKB tumors alone, the combined treatments of S‐Gboxin and MK2206 showed a synergistic inhibitory effect on NCI‐H82‐shCKB tumor growth.